Trial reportThe Journal of pharmacology and experimental therapeutics2019
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
Trial report in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal Naloxone.Journal of clinical pharmacology · 2025Trial
- Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.Drug delivery and translational research · 2022Trial
- Carfentanil stabilizes µ opioid receptor conformations that are ultra-efficient in inhibiting cAMP, resistant to naloxone or nalmefene but sensitive to naltrexone.Archives of toxicology · 2025Article
- Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model-Based Evaluation of Important Pharmacological Attributes.Clinical pharmacology and therapeutics · 2025Article
- Respiratory Depression Associated with Opioids: A Narrative Review.Current treatment options in oncology · 2024Review
- Mechanism-based organization of neural networks to emulate systems biology and pharmacology models.Scientific reports · 2024Article
- Ensuring the Efficacy and Safety of Approved Medications.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.Substance abuse and rehabilitation · 2024Review
- Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids.Frontiers in public health · 2024Review
- American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.Clinical pharmacology in drug development · 2024Article
- Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest.Frontiers in psychiatry · 2024Article
- Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers.Pharmaceutics · 2023Review
- Article
- The role of opioid receptors in modulating Alzheimer's Disease.Frontiers in pharmacology · 2023Review
- Predicting the efficacy of opioid sequestration by intravenous lipid emulsion using biologically relevant in vitro models of drug distribution.Scientific reports · 2022Article
- Treatment of opioid overdose: current approaches and recent advances.Psychopharmacology · 2022Review
- Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride.AAPS PharmSciTech · 2022Article
- Increasingly powerful opioid antagonists are not necessary.The International journal on drug policy · 2022Article
- Hypoxia driven opioid targeted automated device for overdose rescue.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The dramatic rise in overdose deaths linked to synthetic opioids (e.g., fentanyl, carfentanil) may require more potent, longer-duration opiate antagonists than naloxone. Both the high affinity of nalmefene at
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.